Published Aug 12, 2026
Addex Therapeutics: The Pipeline Spun Out to Neurosterix - What Remains Is a 20% Stake and a Cash Countdown
In-depth research on ADXN covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,639 words16 min read
Read report